Patrick Burns Rapuano, MD
Ophthalmology
Headshot of Patrick Burns Rapuano, MD

Patrick Burns Rapuano, MD

Ophthalmology
Accepting new patients
Sees patients age 18 and up
Scheie Eye Institute Radnor
View 1 additional location
Headshot of Patrick Burns Rapuano, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Ophthalmology

My education and training

  • Columbia University College of Physicians and SurgeonsMedical School
  • Pennsylvania HospitalResidency
  • Wills Eye HospitalResidency

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Rapuano is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Rapuano PB, Levin AV, Price JM, Myers JS, Lee D, Shukla AG. Early Experience with Netarsudil in Pediatric Patients: A Retrospective Case Series , Ophthalmol Glaucoma: 2021


Gonzalo-Gil E, Rapuano PB, Ikediobi U, Leibowitz R, Mehta S, Coskun AK, Porterfield JZ, Lampkin TD, Marconi VC, Rimland D, Walker BD, Deeks S, Sutton RE. Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members , Elife, 8: 2019,e44360


Rapuano PB, Mathews PM, Florakis GJ, Trokel SL, Suh LH. Corneal collagen crosslinking in patients treated with dextran versus isotonic hydroxypropyl methylcellulose (HPMC) riboflavin solution: a retrospective analysis , Eye Vis (Lond), 5(10): 2018,23


Mathews PM, De Rojas JO, Rapuano PB, Zemsky CJ, Florakis GJ, Trokel SL, Suh LH. Correlation of Scheimpflug densitometry changes with clinical outcomes after corneal crosslinking , J Cataract Refract Surg, 8(44): 2018,993-1002


Rapuano PB, Scanameo AH, Amponin DE, Paulose SA, Zyablitskaya M, Takaoka A, Suh LH, Nagasaki T, Trokel SL, Paik DC. Antimicrobial Studies Using the Therapeutic Tissue Cross-Linking Agent, Sodium Hydroxymethylglycinate: Implication for Treating Infectious Keratitis , Invest Ophthalmol Vis Sci, 59: 2018,332-337